DNLI Q3 2019 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+1038.4% YoY

Gross Profit

$14M100.0% margin

Operating Income

-$50M-368.7% margin

Net Income

-$46M-340.0% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+224.1%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$33M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$603M

Total Liabilities

$165M

Stockholders' Equity

$438M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$1M	+1038.4%
Gross Profit	$14M	$1M	+1038.4%
Operating Income	-$50M	-$38M	-32.1%
Net Income	-$46M	-$35M	-30.8%

Revenue Segments

Alzheimer's Disease Services

$4M100%